Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs).
PMID: 15183338
2004
The international journal of biochemistry & cell biology
Abstract: In addition, point mutations conferring resistance to NNRTIs (Y181C and L100I) or NRTIs (K65R, L74V, and M184V) partially resensitize the resistant viruses to AZT by inhibiting ATP-phosphorolysis.
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
Abstract: In this study, the active site of the 3TC-resistant (M184V) RT is constructed by a computational method, which clearly shows that the side chain of Val184 occupies the binding site for the nucleoside triphosphates.
Abstract: Therefore, the distance between the side chain of Val184 and the sugar moiety of the nucleoside triphosphate must be closely related to the cross-resistance by M184V RT.
Emtricitabine (FTC) for the treatment of HIV infection.
PMID: 15206508
2004
International journal of clinical practice
Abstract: FTC may be dosed once daily and in vitro is less associated with the M184V mutation, which is classically associated with failure of treatment with lamivudine.
Compartmentalization of drug resistance-associated mutations in a treatment-naive HIV-infected female.
PMID: 15242547
2004
AIDS research and human retroviruses
Abstract: On the other hand vaginal virus contained L63P and M184V mutations in protease and reverse transcriptase, respectively.
Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany.
PMID: 15257882
2004
European journal of medical research
Abstract: CONCLUSION: These analyses should assist in the creation of rules for genotypic drug resistance algorithms for a better reflection of the impact of individual TAM and also the impact of M184I/V on resistance.
Abstract: For didanosine and abacavir, the presence of the M184V mutation and a single TAM did not result in a fold-change increase associated with decreased drug susceptibility.
Abstract: In the presence of the M184I/V mutation, re-sensitization to some drugs, including zidovudine, stavudine and tenofovir was observed despite the presence of a TAM.
Abstract: OBJECTIVES: To analyse the impact of the M184I/V mutation and individual thymidine-associated mutations (TAM) on nucleoside reverse transcriptase inhibitor (NRTI) phenotypic
High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen.
Abstract: In 8/9 cases, Q151M mutation was associated with other substitutions at positions known to be involved in HIV-1 resistance: K65R (n = 6), D67N (n = 1), N69S or T (n = 2), K70R (n = 3), M184V (n = 4), S215Y (n = 1).
2004: which HIV-1 drug resistance mutations are common in clinical practice?
Abstract: For example, only the nucleoside reverse transcriptase inhibitor (NRTI) mutations M184V, M41L T215Y, D67N, K70R and L210W, non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations K103N and Y181C, and protease inhibitor (PI) mutation L90M, occur in more than 10% of samples tested for resistance in this population.
Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.
Abstract: In the 30 failing patients not switched from randomized treatment, we found resistance in two of 12 patients in the RS-arm (M184 V only), four of six patients in the NN-arm [all four had non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations], and seven of 12 patients in the ASD-arm (NRTI mutations only).
HIV mutation literature information.
PMID: 
2004
The international journal of biochemistry & cell biology
Browser Board
Co-occurred Entities
Filtrator
ViMRT